Left Atrial Appendage (LAA) Occluders

This channel includes news and new technology innovations about Left Atrial Appendage (LAA) Occluders. These close off the LAA in patients with atrial fibrillation to prevent the formation of stroke-causing clots in atrial fibrillation (AFib or AF) patients. LAA occlusion is often indicated for patients who do not tolerate anticoagulation therpy or have bleeding risks associated with use of that therapy.

The Watchman FLX will be tested in the CHAMPION-AF trial looks at next-generation transcatheter LAA device as treatment alternative to NOACs for broader population of patients with non-valvular atrial fibrillation.
News | Atrial Fibrillation | October 29, 2020
Oct. 29, 2020 — Boston Scientific initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the...
Positive clinical data from first-in-human studies of the Conformal Medical left atrial appendage closure (LAAC) CLAAS device performed in the U.S. and Prague were presented at 2020 Transcatheter Cardiovascular Therapeutics (TCT) Connect virtual meeting. Two two abstracts were presented by William Gray, M.D., from Lankenau Heart Institute, Wynnewood, Penn., and Vivek Reddy, M.D., from Mount Sinai Hospital in New York. #TCT2020 #TCTconnect
News | Left Atrial Appendage (LAA) Occluders | October 16, 2020
October 16, 2020 — Positive clinical data from first-in-human studies of the Conformal Medical left atrial appendage...
Flexible electronics have been developed to implant in patients to constantly monitor their cardiac condition.

Flexible electronics have been developed to implant in patients to constantly monitor their cardiac condition.

Feature | October 09, 2020 | Udi Nussinovitch M.D., Ph.D.
This is an overview of some of the biggest cardiology technology advances. These innovations are covered in more detail...
Videos | Left Atrial Appendage (LAA) Occluders | October 02, 2020
Horst Sievert, M.D., is the director of the Cardiovascular Center Frankfurt, and associate professor of internal...
Boston Scientific recently introduced the newst iteration of LAA occluder device, the Watchman FLX. It uses small spikes to help better anchor the device and prevent embolization.

Boston Scientific recently introduced the newst iteration of LAA occluder device, the Watchman FLX. It uses small spikes to help better anchor the device and prevent embolization. Read more on this FDA approval.

News | Left Atrial Appendage (LAA) Occluders | August 21, 2020
August 21, 2020 — According to a report published by Research Dive, the rising number of patients suffering from atrial...
The Conformal Medical CLAAS device, a next-generation transcatheter left atrial appendage (LAA) closure occluder for patients with atrial fibrillation (AF). LAA occlusion allows AFib patients to go off of life-long anticoagulation therapy. #LAA #LAAC

The Conformal Medical CLAAS device, a next-generation transcatheter left atrial appendage (LAA) closure occluder for patients with atrial fibrillation (AF). LAA occlusion allows AFib patients to go off of life-long anticoagulation therapy.

News | Left Atrial Appendage (LAA) Occluders | August 06, 2020
August 6, 2020 – Conformal Medical Inc. announced it secured $85 million in Series C financing to support the company’s...
Two of the top pieces of content in July included the FDA clearance for the new Watchman FLX left atrial appendage occluder (left), which includes a video interview with one of the trial investigators. COVID-19 content remained among the top content in July, and one story explained the odd pattern of cardiac cell death in COVID-19 patient autopsies. 

Two of the top pieces of content in July included the FDA clearance for the new Watchman FLX left atrial appendage occluder (left), which includes a video interview with one of the trial investigators. COVID-19 content remained among the top content in July, and one story explained the odd pattern of cardiac cell death in COVID-19 patient autopsies.

Feature | August 03, 2020 | Dave Fornell, Editor
August 3, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC)...
Videos | Left Atrial Appendage (LAA) Occluders | July 24, 2020
Devi G. Nair, M.D., FHRS, director of cardiac electrophysiology, St. Bernards Heart and Vascular Center, Jonesboro, Ark...
The U.S. Food and Drug Administration (FDA) has approved Boston Scientific's next generation Watchman FLX Left Atrial Appendage Closure (LAAC) Device.
News | Left Atrial Appendage (LAA) Occluders | July 22, 2020
July 22, 2020 — The U.S. Food and Drug Administration (FDA) has approved Boston Scientific's next generation Watchman...
PINNACLE FLX Study of New Watchman FLX LAA Occluder Meets Safety and Efficacy Endpoints. #Heartrhythm2020 #HRS20 #HRS2020
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 — Positive 12-month results were announced today from the PINNACLE FLX clinical trial assessing the safety...
The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.20 annual meeting March 28-30, 2020, in Chicago. This includes five late-breaking clinical trial (LBCT) sessions and three featured clinical research sessions. There also are two LBCT deep-dive sessions where the experts will break down the hottest trials and attendees can find out what the impact might be on the practice of cardiology and patients.
Feature | ACC | April 09, 2020 | Dave Fornell, Editor
Here is the list of American College of Cardiology (ACC) practice-changing late-breaking study presentations at the ACC...
Videos | Structural Heart | February 27, 2020
Charles D. Resor, M.D., MSc, assistant director, cardiac catheterization lab, Tufts Medical Center and assistant...
The U.S. Food and Drug Administration (FDA) has approved a the CATALYST trial designed to assess Abbott's Amplatzer Amulet left atrial appendage (LAA) occluder for people with atrial fibrillation (AF or AFib). 
News | Left Atrial Appendage (LAA) Occluders | February 03, 2020
February 3, 2020 — The U.S. Food and Drug Administration (FDA) has approved a the CATALYST trial designed to assess...
Append Medical, developer of a novel left atrial appendage (LAA) closure device to minimize stroke risk in atrial fibrillation (AF) patients, announced that it has been selected from among hundreds of startups as a finalist for the ICI Innovation Award Competition. It uses a transcatheter lasso system so no implant is left behind and eliminates the possibility of embolization.

Append Medical, developer of a novel left atrial appendage (LAA) closure device to minimize stroke risk in atrial fibrillation (AF) patients, announced that it has been selected from among hundreds of startups as a finalist for the ICI Innovation Award Competition. It uses a transcatheter lasso system so no implant is left behind and eliminates the possibility of embolization.

News | Left Atrial Appendage (LAA) Occluders | December 18, 2019
December 18, 2019 — Append Medical, developer of a novel left atrial appendage (LAA) closure device to minimize stroke...
AtriCure Receives Clearance for Expanded Labeling Claims for AtriClip Devices
News | Left Atrial Appendage (LAA) Occluders | August 28, 2019
August 28, 2019 — AtriCure Inc. announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of...